Our Take
Patent cliffs are real; M&A volume reflects panic, not strength—companies are buying to survive, not to grow.
Why it matters
Over $300 billion in branded pharma revenue loses patent protection through 2030 (per PwC). Deal activity concentrates in obesity, immunology, oncology, and RNA—sectors where IP barriers matter most. Watch this metric to spot which therapeutic areas are in genuine scarcity.
Do this week
Biotech founders: map your lead asset's patent expiration date and competing pipeline entry timelines before the next funding round—acquirers will price urgency into every offer.
$65 billion in US pharma deals marks strongest quarter since 2020
US pharma and life sciences M&A deal value in Q1 2026 surpassed $65 billion (per PwC's midyear outlook report), the largest dealmaking quarter in six years. This surge reflects a pivot away from mega-mergers toward what PwC calls "focused and bespoke" mid-cap biotech acquisitions and bolt-on buys.
Deal flow remains concentrated in high-growth, high-margin therapeutic areas: cardiometabolic and obesity, immunology and inflammation, oncology, and rare disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), RNA therapeutics, and antibody-drug conjugates (ADCs) have been particular acquisition targets.
Eli Lilly exemplified the strategy, acquiring 10 companies in 2026, including Centessa for $7.8 billion in January. Q2 momentum continued: Sun Pharma paid $11.75 billion for Organon, and GSK paid $10.6 billion for cancer specialist Nuvalent in April and June respectively (company-reported).
Patent cliff forces large-cap buyers into acquisition mode
The underlying driver is straightforward: branded pharma revenue under patent protection will collapse from 12 percent of global drug sales in 2022 to just 4 percent by 2030 (per GlobalData). Large-cap pharmaceutical companies face more than $300 billion in branded revenue exposure to patent loss (per PwC). The math is brutal. Companies either accelerate in-house R&D (expensive, slow) or buy assets with remaining exclusivity (faster, measurable risk).
Geopolitical headwinds complicate the calculus. Most Favored Nation drug pricing frameworks, tariff threats on pharmaceutical imports, and expanded Inflation Reduction Act negotiations all shape transaction strategy. Large-cap pharma is now in what PwC describes as "active portfolio-replenishment mode," paying premiums for derisked, late-stage assets that directly address LOE gaps.
The biotech IPO window is also reopening, but narrowly. Parabilis Medicines broke the biotech IPO record with $670 million in proceeds earlier this month; Kailera Therapeutics had held the prior record with $625 million two months earlier (both company-reported). IPOs now require "increased proof of clinical success," which pushes many biotechs toward acquisition as a cleaner exit than equity markets.
Lock down patent timelines and competitive intensity
For biotech founders and corporate development leads, the takeaway is immediate. Patent cliffs create artificial scarcity; deal flow will remain heavy through year-end as large-cap buyers close gaps. If your asset sits in a target modality (GLP-1, RNA, ADC, radiopharmaceutical) and has 5-10 years of exclusivity ahead, acquisition interest will intensify. Use that window tactically.
For pharma investors, concentration in cardiometabolic, immunology, and oncology means dry powder will flow toward those sectors. Rare disease and radiopharmaceuticals command premiums. Unfunded biotech in crowded immunology may face harder rounds as buyer preference consolidates.